简要描述:Illumina公司实现生物信息的采集、分析和应用,来改善人类健康。上海易汇生物科技有限公司于17年正式销售Illumina公司基因芯片、二代测序NGS测序仪及相关测序试剂盒等产品Illumina/TruSeq Dual Index Sequencing Primer Box, Paired-End/PE-121-1003/1 EaIllumina 测序试剂盒 PE-121-1003
相关文章
Related Articles详细介绍
品牌 | illumina/美国因美纳 | 货号 | PE-121-1003 |
---|---|---|---|
规格 | 1 kit | 供货周期 | 两周 |
主要用途 | 小型全基因组测序 组合试剂 试剂盒 | 应用领域 | 医疗卫生,化工,生物产业,制药 |
Illumina/TruSeq Dual Index Sequencing Primer Box, Paired-End/PE-121-1003/1 Ea
Illumina 测序试剂盒 PE-121-1003
产品编号: PE-121-1003
美 元 价: $95.00
品 牌: Illumina
产 地: 美国
公 司: Illumina, Inc.
产品分类: 分子类>二代测序>簇生成和测序试剂
公司分类: Cluster Generation & Sequencing Reagents
Illumina公司创立于1998年4月,是遗传变异和生物学功能分析领域的优秀的产品、技术和服务供应商。通过帮助客户加快实现生物信息的采集、分析和应用,来改善人类健康。
Product Highlights:
The primers provided in the TruSeq Dual Index Sequencing Primer Box are required for sequencing the following libraries on the HiSeq 2500, HiSeq 2000, HiSeq 1500, HiSeq 1000 Systems; the HiScanSQ System using TruSeq SBS Kit v3; or the Genome Analyzer System.
The single-read kit should be used with a single-read flow cell, and the paired-end kit with a paired-end flow cell.
Sequencing Kits/ Microarray Kits/Informatics Products/ Clinical Research Products/In Vitro Diagnostic/ Products/Molecular Biology Reagents/ Accessory Products
Illumina 测序试剂盒 PE-121-1003
1999年,Illumina只是一家拥有25人的初创公司,主要销售微阵列芯片(microarray chip),这种芯片可用来检测基因组上特定部位的重要变化。
2007年,Illumina宣布以6亿美元收购基因测序公司Solexa,从而进军基因测序市场。Solexa的基因测试技术较竞争对手快百倍,且价格低廉。
2013年收购了无创产前诊断公司Verinata Health。自2005年以来,Illumina在并购领域的投资已超过12亿美元。
2014年1月,Illumina发布了新款基因测序仪,可以准确测出全基因组序列,而成本还不到1000美元
上海易汇生物科技有限公司于17年正式销售Illumina公司基因芯片、二代测序NGS测序仪及相关测序试剂盒等产品
咨询illumina MiSeq测序试剂盒等产品欢迎您致电 上海易汇生物科技有限公司:1850 1609 238张经理
Illumina公司,致力于新一代测序和芯片技术的生产与开发,提供的产品与应用资讯。Illumina公司创立于1998年4月,是遗传变异和生物学功能分析领域的优秀的产品、技术和服务供应商。通过帮助客户加快实现生物信息的采集、分析和应用,来改善人类健康。
As a startup, Illumina aspired to transform human health. Our initial products enabled researchers to explore DNA at an entirely new scale, helping them create the first map of gene variations associated with health, disease, and drug response. Every breakthrough opened up a new world, and showed us how much further there is to go
While the rate of progress is accelerating exponentially, we are only beginning to understand the clinical significance of the genome. What causes a cancer cell to mutate? What is the origin of a puzzling disease? Is it possible to prevent the next outbreak? Or safeguard the world’s food supply? These are just a few of the challenges that inspire us to push the boundaries of our imagination
Today we are a global leader in genomics – an industry at the intersection of biology and technology. At the most fundamental level, we enable our customers to read and understand genetic variations. We strive to make our solutions increasingly simple, more accessible, and always reliable. As a result, discoveries that were unimaginable even a few years ago are now becoming routine – and are making their way into patient treatment.
We now have the ability to sequence at an unprecedented scale. Collectively, this will give us a much deeper understanding of genetics than ever before. We will begin to truly unlock the power of the genome. These advances will trigger a fundamental shift in healthcare and beyond. Medicine will continue to become more preventive and more precise. We will be healthier, longer. We have only just begun.
At Illumina, our goal is to apply innovative technologies to the analysis of genetic variation and function, making studies possible that were not even imaginable just a few years ago. It is mission critical for us to deliver innovative, flexible, and scalable solutions to meet the needs of our customers. As a global company that places high value on collaborative interactions, rapid delivery of solutions, and providing the highest level of quality, we strive to meet this challenge. Illumina innovative sequencing and array technologies are fueling groundbreaking advancements in life science research, translational and consumer genomics, and molecular diagnostics
产品咨询